Johnson & Johnson's COVID-19 vaccine enters late-stage trial testing


Johnson & Johnson has begun Phase 3 trials of its COVID-19 vaccine in the United States.

According to ABC News, trials for the single-dose vaccine will study up to 60,000 adult participants at nearly 215 sites in America and other countries.

Johnson & Johnson Chief Scientific Officer Dr. Paul Stoffels confirmed that Phase 3 trials would begin immediately, and participants will receive doses in September.

The vaccine candidate was created by Janssen Pharmaceutical Companies, a daughter company of Johnson & Johnson.

Johnson & Johnson is now the fourth company to begin clinical trials for a coronavirus vaccine in the United States, including Pfizer/BioNTech, Moderna, and AstraZeneca.

While the other vaccine candidates require two doses, Johnson & Johnson’s version will be studied as a single-dose vaccine, which Stoffels says should show results.

“We’re convinced that a single dose could be very efficacious,” Stoffels said.

“Four COVID-19 vaccine candidates are in Phase 3 clinical testing in the United States just over eight months after SARS-CoV-2 was identified,” Dr. Anthony Fauci said in a statement.

“This is an unprecedented feat for the scientific community made possible by decades of progress in vaccine technology and a coordinated, strategic approach across government, industry and academia,” Fauci added.

Facebook | Twitter | Instagram